Multi-center study on prediction of response to cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma

Multi-center study on prediction of response to cetuximab-based therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma - Prediction of response to cetuximab-based therapy in patients with head and neck cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000029903

Enrollment

180

Registered

2017-11-09

Start date

2017-11-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent/metastasis head and neck squamous cell carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Of the patients enrolled in "Randomized Phase II multicenter trial comparing modified PFE therapy and modified TPEx therapy for recurrent/metastatic head and neck squamous cell carcinoma" (UMIN 000025436), we agreed on this research document patient.

Exclusion criteria

Exclusion criteria: Patient who can not obtain consent for this study.

Design outcomes

Primary

Measure	Time frame
Correlation between FCGR gene polymorphism and expression of AREG, EREG and effect of cetuximab (Cmab) combination chemotherapy for recurrent/metastatic head and neck cancer	—

Countries

Japan

Contacts

Public ContactYasunao Kogashiwa

Saitama Medical University International Medical Center Department of Head and Neck Surgery, Otolaryngology

y_koga@saitama-med.ac.jp042-984-4111

Outcome results